BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,093 | -84.3% | 65,430 | +61.8% | 0.00% | -85.7% |
| Q2 2023 | $83,286 | -37.6% | 40,430 | 0.0% | 0.02% | -38.2% |
| Q1 2023 | $133,419 | +101.2% | 40,430 | 0.0% | 0.03% | +88.9% |
| Q4 2022 | $66,305 | -63.0% | 40,430 | 0.0% | 0.02% | -64.0% |
| Q3 2022 | $179,000 | +43.2% | 40,430 | -11.0% | 0.05% | +56.2% |
| Q2 2022 | $125,000 | -18.3% | 45,430 | 0.0% | 0.03% | -11.1% |
| Q1 2022 | $153,000 | – | 45,430 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |